Yahoo · Oct 2, 2026
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
CY
NASDAQ · CYTK
Cytokinetics, Incorporated
Healthcare · Biotechnology
$61.35
Down-$1.35 (-2.15%)
Updated Oct 7, 2026, 4:08 AM
SID Score
4.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.23B
- P/E ratio
- -9.7
- Dividend yield
- 0.00%
- 52-week range
- $54.30 – $88.31
- Volume
- 3.23M
- Avg. volume
- 2.02M
Price performance · CYTK
CYTK price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
CYTK closed at $61.35 after 21 trading sessions, down 18.58% for the selected period.
- Last close
- $61.35
- Period change
- -18.58%
- Period low
- $61.35
- Period high
- $75.35
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $62.20 | $62.525 | $60.68 | $61.35 | 3.23M |
| Oct 5, 2026 | $65.60 | $65.755 | $62.19 | $62.70 | 3.23M |
| Oct 2, 2026 | $66.45 | $66.91 | $64.49 | $65.60 | 2.65M |
| Oct 1, 2026 | $65.73 | $67.27 | $65.30 | $65.62 | 1.72M |
| Sep 30, 2026 | $65.90 | $66.92 | $65.25 | $65.91 | 2.98M |
| Sep 29, 2026 | $65.91 | $66.52 | $64.38 | $65.64 | 2.4M |
| Sep 28, 2026 | $64.58 | $66.41 | $64.25 | $66.16 | 2.55M |
| Sep 25, 2026 | $65.66 | $65.945 | $64.44 | $64.66 | 1.6M |
| Sep 24, 2026 | $65.37 | $66.47 | $64.89 | $65.66 | 1.84M |
| Sep 23, 2026 | $67.02 | $67.385 | $64.725 | $65.81 | 2.05M |
| Sep 22, 2026 | $68.07 | $69.56 | $67.48 | $67.59 | 2.39M |
| Sep 21, 2026 | $69.30 | $69.495 | $67.35 | $67.56 | 1.6M |
| Sep 18, 2026 | $70.18 | $70.18 | $68.15 | $68.78 | 4.87M |
| Sep 17, 2026 | $70.64 | $71.05 | $68.915 | $69.92 | 1.4M |
| Sep 16, 2026 | $69.52 | $70.68 | $68.67 | $69.39 | 2.21M |
| Sep 15, 2026 | $72.13 | $72.19 | $68.55 | $69.31 | 2.58M |
| Sep 14, 2026 | $73.505 | $74.65 | $72.34 | $72.45 | 1.53M |
| Sep 11, 2026 | $74.66 | $75.98 | $73.50 | $73.77 | 1.72M |
| Sep 10, 2026 | $73.23 | $75.10 | $73.13 | $73.62 | 1.44M |
| Sep 9, 2026 | $74.31 | $74.89 | $73.52 | $74.11 | 1.42M |
| Sep 8, 2026 | $72.39 | $76.805 | $72.39 | $75.35 | 1.92M |
Latest CYTK news
The latest Smart Investors Daily articles mentioning CYTK.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CYTK research
Overview
Company profile and research snapshot.
Company profile
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $79.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 31, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | JP Morgan | Overweight | — |
| Aug 13, 2026 | Barclays | Overweight | — |
| Aug 10, 2026 | Truist Securities | Buy | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 2, 2026
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026. Late-Breaking Clinical Trial Presentations Title: Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Res
SeekingAlpha · Sep 30, 2026
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. Click for this updated look at LXRX.
Yahoo · Sep 30, 2026
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of ASPEN-HCM (Aficamten Study of Patient Experience and Novel Outcomes in Symptomatic Obstructive HCM), a prospective, multicenter, observational real-world study evaluating MYQORZO® (aficamten) in adult patients w
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
